Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia

Huafeng Wang; Chang Yang; Ting Shi; Yi Zhang; Jiejing Qian; Yungui Wang; Yongxian Hu; Liping Mao; Xiujin Ye; Fang Liu; Zhenfang Xi; Lihong Shou; Caiyun Fu; Hua Naranmandura; Jie Jin; Hong-Hu Zhu

doi:10.1038/s41408-022-00621-9

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia

Blood Cancer J. 2022 Jan 28;12(1):20. doi: 10.1038/s41408-022-00621-9.

Authors

Huafeng Wang^#^{1

2

3

4}, Chang Yang^#^{1

5}, Ting Shi^#^{1

2

3}, Yi Zhang^#^{1

2

3}, Jiejing Qian^#^{1

2

3}, Yungui Wang^{1

2

3}, Yongxian Hu^{3

6}, Liping Mao^{1

2

3}, Xiujin Ye^{1

2

3}, Fang Liu⁷, Zhenfang Xi⁸, Lihong Shou⁹, Caiyun Fu¹⁰, Hua Naranmandura^{11

12}, Jie Jin^{13

14

15

16}, Hong-Hu Zhu^{17

18

19

20

21}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
² Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
³ Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, PR China.
⁴ Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China.
⁵ Department of Public Health, Zhejiang University School of Medicine, Hangzhou, PR China.
⁶ Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
⁷ Department of Hematology, Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China.
⁸ Department of Hematology, Linfen People's Hospital, Linfen, Shanxi, PR China.
⁹ Department of Hematology, The Central Hospital of Huzhou City, Huzhou, People's Republic of China.
¹⁰ College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
¹¹ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China. [email protected].
¹² Department of Public Health, Zhejiang University School of Medicine, Hangzhou, PR China. [email protected].
¹³ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China. [email protected].
¹⁴ Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China. [email protected].
¹⁵ Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, PR China. [email protected].
¹⁶ Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China. [email protected].
¹⁷ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China. [email protected].
¹⁸ Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China. [email protected].
¹⁹ Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, PR China. [email protected].
²⁰ Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China. [email protected].
²¹ Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China. [email protected].

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Male
Middle Aged
Mutation / drug effects
Philadelphia Chromosome / drug effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Pyridazines / therapeutic use*
Retrospective Studies
Sulfonamides / therapeutic use*
Young Adult

Substances

Bridged Bicyclo Compounds, Heterocyclic
Imidazoles
Pyridazines
Sulfonamides
ponatinib
venetoclax